Based on this foundation, a hydrogel-based delivery platform was engineered, which was designed to co-deliver tumor-targeting CuS NPs and the immune-suppressive cell-targeting CD36 inhibitor sulfo-N-succinimidyl oleate (SSO), ultimately forming iF-CuS-M/SSO@Gel. The gene discussed is CD36; the disease is neoplasm.